American Society of Clinical Oncology

How to approach value in oncologyAn eye-opening study by Precision for Value assesses cancer value frameworks.
HHS makes clinical trials more transparentHHS finalized rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.
Genomic profile products enhanced to better predict immunotherapy responseFoundation Medicine, based in Cambridge, Mass., announced in late August the addition of new clinical markers to its genomic profile products FoundationOne and FoundationOne Heme.
Experts debate best treatment for metastatic colorectal cancer patientsDe-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
Genetic tests guide cancer therapy, improve efficacyAt the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.
Cancer care model benefits healthcare stakeholdersA value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.
ASCO set to compare value of cancer drugsThe American Society of Clinical Oncology is asking for comments on its ASCO Value Framework, which compares the value of new cancer therapies with established treatments.
Ibrutinib interim data promising in patients with chronic graft-versus-host-diseaseIbrutinib may be a safe and potentially effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were refractory to steroid treatment or steroid-dependent, suggested interim data presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Combo therapy yields intriguing results in melanoma progressionResults of a new study on combination drugs used to treat melanoma were presented at the 2015 American Society of Clinical Oncology meeting in Chicago. Researchers showed that a combination of ipilimumab and nivolumab stopped the advancement of melanoma for nearly a year in 58% of cases.